Phoenix RX

Phoenix Molecular Designs (PhoenixMD) is a clinical-stage biopharmaceutical company focused on developing first-in-class precision oncology therapeutics. The company's primary focus is on inhibiting Ribosomal S6 Kinase (RSK), a key driver in tumor growth and resistance to standard therapies. Its lead candidate, PMD-026, is an oral pan-RSK inhibitor currently being evaluated in Phase 2 clinical trials for breast cancer, specifically targeting patients with high RSK2 expression. PhoenixMD utilizes a companion diagnostic strategy to identify patients most likely to benefit from its targeted therapies, aiming to provide more effective options for refractory cancers like triple-negative breast cancer.